Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

2.

Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer.

Engel-Nitz NM, Hao Y, Becker LK, Gerdes R.

J Comp Eff Res. 2015 Aug;4(4):303-14. doi: 10.2217/cer.15.19.

PMID:
26274792
3.

Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes.

Engel-Nitz NM, Eckert B, Song R, Koka P, Hulbert EM, McPheeters J, Teitelbaum A.

BMC Clin Pathol. 2014 Apr 27;14:17. doi: 10.1186/1472-6890-14-17. eCollection 2014.

4.

Service setting impact on costs for bevacizumab-treated oncology patients.

Engel-Nitz NM, Yu EB, Becker LK, Small A.

Am J Manag Care. 2014 Nov 1;20(11):e515-22.

5.

An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data.

Whyte JL, Engel-Nitz NM, Teitelbaum A, Gomez Rey G, Kallich JD.

Med Care. 2015 Jul;53(7):e49-57. doi: 10.1097/MLR.0b013e318289c3fb.

PMID:
23524464
6.

Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.

Garris C, Jhingran P, Bass D, Engel-Nitz NM, Riedel A, Dennis G.

J Med Econ. 2013;16(5):667-77. doi: 10.3111/13696998.2013.778270. Epub 2013 Mar 11.

PMID:
23425294
7.

Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy.

Priest J, Buikema A, Engel-Nitz NM, Cook CL, Cantrell CR.

Popul Health Manag. 2012 Apr;15(2):101-12. doi: 10.1089/pop.2011.0008. Epub 2012 Feb 7.

PMID:
22313439
8.

Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data.

Lau EC, Mowat FS, Kelsh MA, Legg JC, Engel-Nitz NM, Watson HN, Collins HL, Nordyke RJ, Whyte JL.

Clin Epidemiol. 2011;3:259-72. doi: 10.2147/CLEP.S23690. Epub 2011 Oct 11.

9.

Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.

Engel-Nitz NM, Alemayehu B, Parry D, Nathan F.

Cancer Manag Res. 2011;3:233-45. doi: 10.2147/CMR.S21033. Epub 2011 Jul 4.

10.

Costs and outcomes of noncardioembolic ischemic stroke in a managed care population.

Engel-Nitz NM, Sander SD, Harley C, Rey GG, Shah H.

Vasc Health Risk Manag. 2010 Oct 5;6:905-13. doi: 10.2147/VHRM.S10851.

11.

Antihypertensive medication changes and blood pressure goal achievement in a managed care population.

Engel-Nitz NM, Darkow T, Lau H.

J Hum Hypertens. 2010 Oct;24(10):659-68. doi: 10.1038/jhh.2010.2. Epub 2010 Jan 28.

PMID:
20107489
12.

Cardiovascular events and insulin therapy: a retrospective cohort analysis.

Engel-Nitz NM, Martin S, Sun P, Buesching D, Fonseca V.

Diabetes Res Clin Pract. 2008 Jul;81(1):97-104. doi: 10.1016/j.diabres.2008.02.011. Epub 2008 Apr 15.

PMID:
18417242

Supplemental Content

Loading ...
Support Center